pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,604 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1183Endpoints903BioPharma Dive347BioSpace317Fierce Biotech301onclive165raps106globenewswire health
therapy area
allOncology7751Rare Disease1891Cardiology1775Immunology1511Hematology1328Vaccines1204Pulmonology
  • Trump administration proposes rule to close Medicare drug price-negotiation loophole
    The White House announced a proposal to tighten a policy that stops drugmakers from sidestepping Medicare price negotiations by adding new active ingredients to existing products. The change would…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Enliven Therapeutics raises $400M as Jazz's Zepzelca misses confirmatory trial
    Enliven Therapeutics, a biotech based in Burlingame, California, announced that it priced a public offering of its common stock that raised about $400 million. The capital raise follows the compan…
    Endpoints · 2mo agoDealNeutral↗ source
← prev
page 73 of 105
next →
73
fda recalls70
fda medwatch60
fda press38
1200
Psychiatry & CNS870
Ophthalmology502
Pain482
Endocrinology & Metabolism481
Infectious Disease444
  • Novo's M&A head joins Forbion as Perrigo CEO steps down over conduct concerns
    Novo's senior M&A executive has left the company to take a role at Dutch investment firm Forbion. Forbion, which manages a portfolio of biotech companies, has been active in M&A and aims to increa…
    Endpoints · 2mo agoNeutral↗ source
  • Engaging Religious Leaders Key to Containing Ebola in DRC and Uganda
    An opinion piece by Olivia Wilkinson and Katherine Marshall stresses that Ebola spreads through caring acts such as tending the sick and handling burials, and that mistrust and misinformation often…
    STAT · 2mo agoPositive↗ source
  • Amgen seeks FDA review of Tavneos to determine continued market availability
    Amgen has formally asked the U.S. Food and Drug Administration to re-examine the data supporting its drug Tavneos (avacopan). Tavneos is indicated for a rare form of vasculitis and the request sig…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
  • Eli Lilly backs health-tech startup Abridge to expand clinical trial recruitment
    Eli Lilly’s venture arm has made an investment in Abridge, a health‑technology company that is moving into the clinical trial recruitment space. The funding is intended to help Abridge broaden its…
    Endpoints · 2mo agoDealPositive↗ source
  • Veteran researcher warns new OMB grant rule could politicize U.S. science
    David J. Skorton, president of the Association of American Medical Colleges, writes that after four decades in research he has never seen a threat to science like the new grantmaking rule being con…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Hospital finance leaders call for ending billing friction that drives high costs
    At the Healthcare Financial Management Association’s annual meeting in Maryland, hospital finance executives gathered to discuss the persistent problem of affordability in health care. While the hi…
    STAT · 2mo agoNegative↗ source
  • Sciwind Biosciences seeks additional partners for obesity drug ecnoglutide after deals with Pfizer and Verdiva Bio
    Sciwind Biosciences, a Chinese biotech, has licensed its GLP-1 obesity candidate ecnoglutide to two Western companies. The first agreement grants Pfizer rights to develop and commercialize the dru…
    Endpoints · 2mo agoDealPositive↗ source
  • AstronauTx appoints Michelle Mellion as new chief medical officer
    STAT+ columnist Ed Silverman reports on the latest personnel moves in the pharmaceutical sector, a regular feature that tracks hires, promotions and departures. The most recent addition is Michell…
    STAT · 2mo agoPositive↗ source
  • WuXi AppTec Files Lawsuit Against Pentagon Over Chinese Military Designation
    WuXi AppTec, a major contract manufacturing organization in China, has filed a lawsuit in U.S. federal court. The suit challenges the U.S. Department of Defense's decision to place the company on…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
  • ADA apologizes after expelling five experts for distributing editorial at diabetes conference
    At the American Diabetes Association's annual meeting in New Orleans, five diabetes researchers were expelled and warned they could be arrested after distributing paper copies of an editorial. The…
    STAT · 2mo agoNegative↗ source
  • Blood Cancer United acquires remaining supply of discontinued investigational drug Luvelta
    Blood Cancer United, a nonprofit focused on blood cancers, is purchasing the remaining inventory of Luvelta, an investigational cancer drug that has been discontinued. The acquisition aims to pres…
    STAT · 2mo agoNeutral↗ source
  • Biopharma exec pay reveals quirky perks like private jets and wildfire relief grants
    A recent review of thousands of biopharma C‑suite compensation packages found that most line items blend into the massive totals, but a few stand out for their unusual nature. Among the highlighte…
    Endpoints · 2mo agoNeutral↗ source
  • RFK Jr.’s “Make America Healthy Again” pledge shows mixed progress, tracking successes and gaps
    STAT is monitoring the promises made by Robert F. Kennedy Jr. under his “Make America Healthy Again” agenda, cataloguing which goals have been met, which remain incomplete, and which have not been…
    STAT · 2mo agoNeutral↗ source
  • Chile releases new data on effectiveness of food warning labels
    Chile's health officials have released fresh data that assess how well the country's food warning label system works. The findings add to ongoing research about whether mandatory labels influence…
    STAT · 2mo agoNeutral↗ source
  • Federal probe finds private Medicare Advantage plans deny rehab care, then reverse on appeal
    A federal investigation has revealed that the nation's largest Medicare Advantage insurers routinely deny post-acute rehabilitative services to older and disabled beneficiaries. The review found t…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Actuaries predict continued rise in healthcare costs for next year
    A recent survey of actuaries from 27 health plans that serve both employer groups and individual exchange markets shows early signs of where health-care spending is headed. The respondents expect…
    Endpoints · 3mo agoNegative↗ source
  • DHL in talks with major pharma firms to manage sites amid ongoing trade disruptions
    DHL's healthcare logistics division is currently in discussions with several leading pharmaceutical manufacturers. The drugmakers are exploring options for DHL to either assume control of their ma…
    Endpoints · 3mo agoDealNeutral↗ source
  • Summit Therapeutics cancels $500 million public offering amid weak market conditions
    Summit Therapeutics announced it is no longer pursuing a $500 million public offering, citing unfavorable market conditions. The biotech sector has recently seen record‑setting initial public offe…
    Endpoints · 3mo agoDealNegative↗ source
  • Novartis expands molecular glue program as Medicare drug spending surges and biotech firms report new data and funding
    Novartis announced it is deepening its investment in molecular glue technology, a platform that aims to target previously undruggable proteins. The move signals the company’s confidence in the appr…
    STAT · 3mo agoPositive↗ source
  • Kardigan targets $320 million IPO to fund three late-stage heart drugs
    Kardigan, a biotech focused on cardiovascular therapies, announced plans for an initial public offering that aims to raise about $320 million. The proceeds are intended to support the development…
    Endpoints · 3mo agoDealNeutral↗ source
  • FDA grants emergency use authorization for generic Nitenpyram tablets to treat New World screwworm in dogs and cats
    The U.S. Food and Drug Administration has issued an Emergency Use Authorization for generic Nitenpyram tablets to treat New World screwworm infestations in dogs, puppies, cats and kittens that weig…
    fda press · 3mo agoRegulatoryPositive↗ source
  • Enliven Therapeutics' early-stage study shows 48% major molecular response in CML patients
    A targeted therapy from Enliven Therapeutics, ELVN-001, produced major molecular responses in 48% of participants with chronic myeloid leukemia (CML) in a 24‑week, early‑stage trial. The study eval…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Synthetic lethality hype may spark new wave of biotech mergers
    The piece highlights rising enthusiasm for synthetic lethality as a cancer‑treatment strategy, especially after recent data releases. In an early‑stage trial, Tango Therapeutics reported that pati…
    STAT · 3mo agoPositive↗ source